PVLA
Palvella Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$146.15Close
$1.8BMarket cap
$75.06 – $158.1352-week range
Nov 5, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 91 · stronger than 91% of stocks over 12 months
Cautions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
8%
1wk
up 16.8%
price change
1mo
up 6.0%
price change
12-month return
up 86%
market up 11% ·
its own up 84%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
64.7×
price / book
Earnings yield
down 2.2%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 92%
return on equity
Free cash margin
—
-$25.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.1%
$7.47 a day · 2×ATR $131.20
RS
91 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.3×
vs 50-day average
Up/down volume
0.86
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 12.4% over the year, from 11m to 12m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+8% vs market2 sessions after results
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $29.3M | $31.4M | $25.9M | $42.8M | — | — |
| Operating income | -$33.9M | -$51.8M | -$43.5M | -$11.9M | -$14.1M | -$38.6M |
| Net income | -$37.2M | -$45.7M | -$33.3M | $18.7M | -$17.4M | -$41.7M |
| Net margin | -127% | -146% | -128% | 44% | — | — |
| Earnings per share | -$0.68 | -$0.71 | -$0.45 | $10.42 | -$7.83 | -$3.71 |
| Free cash flow | -$48.6M | -$8.6M | -$61.0M | -$13.9M | -$10.8M | -$25.0M |
| Free cash margin | -166% | -27% | -235% | -32% | — | — |
| Cash | $70.4M | $117.8M | $38.6M | $7.3M | $83.6M | $58.0M |
| Shareholders' equity | $31.0M | $50.8M | -$93.8M | -$74.5M | $62.6M | $28.0M |
| Shares outstanding | 56m | 72.22m | 74.52m | 1.77m | 11.01m | 12.38m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 31, 2026 | Annual ↗ | Dec 31, 2025 | 90d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 14, 2025 | Quarterly ↗ | Jun 30, 2025 | 45d |
| May 15, 2025 | Quarterly ↗ | Mar 31, 2025 | 45d |
| Mar 31, 2025 | Annual ↗ | Dec 31, 2024 | 90d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 14, 2024 | Quarterly ↗ | Jun 30, 2024 | 45d |
| May 15, 2024 | Quarterly ↗ | Mar 31, 2024 | 45d |
| Mar 29, 2024 | Annual ↗ | Dec 31, 2023 | 89d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Other events ↗ |
| Aug 4, 2026 | Results · Regulation FD ↗ |
| Jul 14, 2026 | Other events ↗ |
| Jun 30, 2026 | Director or officer change ↗ |
| Jun 16, 2026 | Director or officer change · Shareholder vote ↗ |
| May 20, 2026 | Other events ↗ |
| May 15, 2026 | Other events ↗ |
| May 13, 2026 | Other events ↗ |
| May 7, 2026 | Results · Regulation FD ↗ |
| Apr 13, 2026 | Director or officer change ↗ |
| Apr 7, 2026 | Other events ↗ |
| Mar 31, 2026 | Results · Regulation FD ↗ |